This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bubley GJ et al. (1999) Eligibility and response guidelines for phase II trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461–3467
Peehl DM (2001) Basic science of hormonal therapy for prostate cancer. Rev Urol 3 (Suppl 3): S15–S22
Shah RB et al. (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64: 9209–9216
Acknowledgements
The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Dr Berry is a speaker for Aventis.
Glossary
- CR; COMPLETE RESPONSE
-
Normalization of PSA to <4 ng/ml confirmed for 1 month
- PR; PARTIAL RESPONSE
-
A 50% fall in PSA maintained for 4 weeks
- SD; STABLE DISEASE
-
PSA levels which do not rise by >25% or fall by >50% over 8 weeks
- PD; DATE OF PROGRESSION
-
Date of first CT scan to show new lesions or 25% increase in previously measured disease, or date of first sustained rise in PSA
Rights and permissions
About this article
Cite this article
Berry, W. Re-induction of hormonal sensitivity in hormone-refractory prostate cancer—fact or fiction?. Nat Rev Clin Oncol 2, 180–181 (2005). https://doi.org/10.1038/ncponc0136
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0136
